Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 14 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Lurbinectedin for platinum resistant ovarian cancer Lurbinectedin (PM01183; Zepzelca) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2017 View  |  Download
Mirvetuximab Soravtansine for Platinum-resistant Ovarian Cancer Mirvetuximab soravtansine (IMGN853) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Niraparib for advanced ovarian, fallopian tube or primary peritoneal cancer - maintenance therapy Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Nivolumab for platinum-resistant advanced or recurrent ovarian cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2017 View  |  Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications